For preclinical and clinical study design, determining the optimal drug dosage is critical. Receptor occupancy (RO) models are used to understand a drug’s behavior and determine safe drug dosage levels. Learn how flow cytometry can help inform decision points in nonclinical and clinical development.
A virtual biotech company chose Covance to conduct two Phase III clinical trials for a new antibiotic treating life-threatening skin infections, such as methicillin-resistant staphylococcus aureus (MRSA).
Prior to vaccine development, the United States (US) had 500,0001 and 150,0002 annual cases of measles and mumps respectively. Initially created as stand-alone vaccines in the 1960s, cases for measles and mumps had dramatic drops in incidence post vaccination, with an additional decline in cases for both diseases after the introduction of the MMR (measles, mumps and rubella) vaccine in 19722. The requirement for a second MMR dose (after measles and mumps outbreaks in the late 1980s), as well as policy initiatives such as the US federally-funded Vaccines for Children Program in 1994,3 lead to further declines in infection.